Global Blood Therapeutics (NASDAQ: GBT) and Caladrius Biosciences (NASDAQ:CLBS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, analyst recommendations and profitability.
Risk and Volatility
Global Blood Therapeutics has a beta of 4.21, meaning that its stock price is 321% more volatile than the S&P 500. Comparatively, Caladrius Biosciences has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.
This table compares Global Blood Therapeutics and Caladrius Biosciences’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Global Blood Therapeutics||N/A||N/A||-$95.43 million||($2.47)||-13.44|
Global Blood Therapeutics is trading at a lower price-to-earnings ratio than Caladrius Biosciences, indicating that it is currently the more affordable of the two stocks.
This table compares Global Blood Therapeutics and Caladrius Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Global Blood Therapeutics||N/A||-38.92%||-36.49%|
Insider and Institutional Ownership
86.1% of Global Blood Therapeutics shares are held by institutional investors. Comparatively, 6.5% of Caladrius Biosciences shares are held by institutional investors. 5.3% of Global Blood Therapeutics shares are held by company insiders. Comparatively, 13.1% of Caladrius Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This is a summary of recent ratings for Global Blood Therapeutics and Caladrius Biosciences, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Global Blood Therapeutics||0||0||11||0||3.00|
Global Blood Therapeutics currently has a consensus target price of $55.73, indicating a potential upside of 67.85%. Caladrius Biosciences has a consensus target price of $6.75, indicating a potential upside of 88.55%. Given Caladrius Biosciences’ higher probable upside, analysts clearly believe Caladrius Biosciences is more favorable than Global Blood Therapeutics.
Global Blood Therapeutics beats Caladrius Biosciences on 6 of the 9 factors compared between the two stocks.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company’s GBT440 is an investigational drug that increases hemoglobin’s affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.
What are top analysts saying about Global Blood Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Global Blood Therapeutics Inc. and related companies.